Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) - Laporan Laba Rugi (TTM)

Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock)
US ˙ NasdaqCM ˙ US00653A1079

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 3 4 4 6 6 6 9 12 18 27 71 71 71 60 18 141 175 178 180 65
Change (%) 24.31 -8.26 71.41 0.16 -1.36 51.08 26.30 49.47 54.80 162.17 -0.57 0.44 -15.19 -69.55 670.56 23.74 1.71 0.90 -63.77
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 86 92 95 103 107 111 123 129 30 128 117 112 221 127 136 147 143 149 144 129
Change (%) 6.30 3.54 8.87 4.01 3.47 11.02 4.76 -77.16 332.90 -8.77 -4.10 97.79 -42.76 7.64 7.70 -2.38 4.17 -3.67 -10.42
% of Revenue 2,705.56 2,313.49 2,611.13 1,658.39 1,722.20 1,806.64 1,327.62 1,101.24 168.24 470.48 163.71 157.91 310.96 209.87 741.74 103.67 81.79 83.77 79.97 197.73
Gross Operating Profit -83 -88 -91 -97 -101 -105 -114 -117 -12 -101 -45 -41 -150 -66 -118 -5 32 29 36 -64
Change (%) 5.60 4.07 6.38 4.26 3.77 8.68 3.01 -89.81 740.39 -54.91 -9.63 265.90 -55.83 77.89 -95.59 -713.91 -9.32 24.49 -276.78
% of Revenue -2,605.56 -2,213.49 -2,511.13 -1,558.39 -1,622.20 -1,706.64 -1,227.62 -1,001.24 -68.24 -370.48 -63.71 -57.91 -210.96 -109.87 -641.74 -3.67 18.21 16.23 20.03 -97.73
SG&A 43 46 50 54 56 57 60 61 63 63 59 61 68 64 70 72 70 81 83 84
Change (%) 5.80 9.95 6.44 4.05 2.76 5.21 1.68 2.68 0.70 -7.07 4.13 10.62 -4.99 7.93 3.02 -2.86 16.78 2.32 1.28
% of Revenue 1,359.48 1,157.02 1,386.70 861.10 894.56 931.94 649.00 522.48 358.93 233.49 82.76 86.68 95.46 106.94 378.99 50.67 39.78 45.67 46.31 129.47
R&D 105 -105
Change (%)
% of Revenue 596.88 -147.27
OpEx 129 137 145 157 163 168 184 191 197 191 175 173 184 191 206 218 213 230 227 213
Change (%) 6.13 5.68 8.03 4.03 3.23 9.05 3.75 3.47 -3.05 -8.21 -1.34 6.42 3.67 7.73 6.12 -2.54 8.29 -1.55 -6.13
% of Revenue 4,065.04 3,470.52 3,997.82 2,519.49 2,616.76 2,738.58 1,976.62 1,623.72 1,124.05 703.97 246.48 244.59 259.16 316.80 1,120.73 154.34 121.57 129.44 126.29 327.19
Operating Income -126 -133 -142 -151 -157 -162 -174 -179 -180 -164 -104 -102 -113 -131 -187 -77 -38 -52 -47 -148
Change (%) 5.67 6.09 6.40 4.19 3.41 7.45 2.55 0.45 -8.70 -36.42 -1.86 10.56 15.53 43.38 -58.98 -50.89 38.83 -9.90 213.16
% of Revenue -3,965.04 -3,370.52 -3,897.82 -2,419.49 -2,516.76 -2,638.58 -1,876.62 -1,523.72 -1,024.05 -603.97 -146.48 -144.59 -159.16 -216.80 -1,020.73 -54.34 -21.57 -29.44 -26.29 -227.19
Interest Expense -1 -1 -2 -3 -5 -6
Change (%) 210.84 104.77 56.18 8.34
% of Revenue -12.75 -0.37 -0.93 -1.88 -2.91 -8.70
Net Income -123 -130 -140 -149 -156 -158 -171 -176 -175 -165 -114 -91 -95 -114 -163 -72 -45 -71 -70 -170
Change (%) 5.90 7.38 6.58 4.68 1.44 7.91 3.20 -0.56 -5.49 -31.01 -20.26 4.59 19.61 43.50 -55.63 -38.60 59.08 -1.30 142.87
% of Revenue -3,858.13 -3,286.81 -3,847.09 -2,391.97 -2,499.92 -2,570.99 -1,836.30 -1,500.42 -998.26 -609.46 -160.39 -128.63 -133.94 -188.90 -890.13 -51.25 -25.43 -39.78 -38.91 -260.82

Source: Capital IQ

Other Listings
DE:473A € 0.04
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista